Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Summary

This is a multi-center, open-label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).

Timeline

Start

2025-09

Primary completion

2026-06

Completion

2027-06

Outcome

Outcome not reported

Stopped: “Sponsor changed product development plan”

Drugs

Indications